Literature DB >> 3306520

Contraception for the perimenopausal patient.

G V Upton.   

Abstract

All the existing data show that combination estrogen/progestogen therapy is mandatory if any replacement therapy is to be given to the woman over age 40. Sufficient evidence has indicated that estrogen alone is inadequate; progestogen must be given to prevent endometrial hyperplasia, lower the risk of breast cancer, and prevent bone loss. In the premenopausal woman, such therapy should also provide contraception. Because of the lack of minimal dose products fulfilling such criteria, many physicians will allow women to continue with their contraceptive if they do not smoke and have no other contraindications. It will remain to be seen if a product close to ideal can be found to fulfill the contraceptive and therapeutic needs of women traversing the most physiologically hazardous period of their lives.

Entities:  

Keywords:  Biological Aging--women; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Endocrine System; Endometrial Effects; Endometrium; Estrogens--therapeutic use; Family Planning; Genitalia; Genitalia, Female; Hormones; Lipid Metabolic Effects; Lipids; Menopause; Metabolic Effects; Physiology; Progestational Hormones--pharmacodynamics; Progestational Hormones--therapeutic use; Reproduction; Urogenital System; Uterus

Mesh:

Substances:

Year:  1987        PMID: 3306520

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  1 in total

1.  Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.

Authors:  J C Prior; S A Kirkland; L Joseph; N Kreiger; T M Murray; D A Hanley; J D Adachi; Y M Vigna; C Berger; L Blondeau; S A Jackson; A Tenenhouse
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.